Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective β3-adrenoceptor agonist in humans

Diabetes

Volumn 47, Issue 10, 1998, Pages 1555-1561

  Weyer, Christian ^a,b   Tataranni, P Antonio ^a   Snitker, Søren ^a   Danforth Jr , Elliot ^a   Ravussin, Eric ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; PLACEBO;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY ACID OXIDATION; HORMONE ACTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT;

ADRENERGIC BETA-AGONISTS; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; DIOXOLES; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; LEPTIN; LIPID METABOLISM; MALE; OXIDATION-REDUCTION; PROTEINS;

EID: 0031661901     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.10.1555     Document Type: Article

References (54)

1. Arch JRS, Ainsworth AT: Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 38:549-558, 1983
2. Arch JRS, Ainsworth AT, Ellis RDM, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P: Treatment of obesity with thermogenic β-adrenoceptor agonists. Int J Obes 8:1-11, 1984
3. 3-adrenoceptor agonist, in yellow KK mice. Life Sci 54:491-498, 1994
4. 3-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Eur J Endocrinol 131:97-102, 1994
5. Yen TT, Fuller RW, Hemrick-Leukkce SK, Dininger NB: The antiobesity and metabolic activities of LY104119 in obese and normal mice. Int J Obes 8:69-87, 1984
6. 3-Adrenergic agonist, Zeneca ZD2079, improves glucose homeostasis in insulin-resistant rodents (Abstract). Diabetes 46 (Suppl. 1):A212, 1987
7. 3-adrenoceptor agonist (CL 316,243). Drug Dev Res 32:69-76, 1994
8. 3-specific adrenoceptor agonist, enhances insulin-mediated glucose disposal in nonobese rats. Diabetes 46:1257-1263, 1997
9. 3-adrenoceptor agonists. Drugs Future 18:529-549, 1993
10. 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 20:191-199, 1996
11. 3-adrenoceptor agonists in the treatment of obesity and diabetes. Curr Opin Endocrinol Diab 3:59-65, 1996
12. 3-adrenergic receptor. Eur J Endocrinol 136:362-365, 1997
13. Arner P: The β-adrenergic receptor - a cause or cure of obesity? N Engl J Med 333:382-383, 1995
14. 3-adrenergic receptors (Editorial). J Clin Invest 95:923, 1995
15. Munro JF, Chapman BJ, Robb GH, Zed C: Clinical studies with thermogenic drugs. In Recent Advances in Obesity Research. Vol 5. Berry EM, Eliahou SH, Shafir E, Eds. London, Libbey, 1987, p. 155-159
16. 3-adrenoceptor agonist BRL 26830A. Int J Obes 16:685-694, 1992
17. 3-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women. Int J Obes 18:313-322, 1994
18. Scheidegger K, Robbins DC, Danforth E Jr: Effects of chronic β-receptor stimulation on glucose metabolism. Diabetes 33:1144-1149, 1984
19. Connacher AA, Lakie M, Powers N, Elton RA, Walsh EG, Jung RT: Tremor and the anti-obesity drug BRL 26830A. Br J Clin Pharmacol 30:613-615, 1990
20. 3-adrenoceptor agonist BRL 26830A. Br J Clin Pharmacol 37:363-369, 1994
21. Acheson KJ, Ravussin E, Schoeller DA, Christin L, Bourquin L, Baertschi P, Danforth E Jr, Jequier E: Two-week stimulation or blockade of the sympathetic nervous system in man: influence on body weight, body composition, and twenty-four-hour energy expenditure. Metabolism 37:91-98, 1988
22. 3-adrenoceptors: a promising antidiabetic and antiobesity agent. J Med Chem 35:3081-3084, 1992
23. 3-adrenergic agonist CL 316,243 in obese Zucker (ZDF) rats. Am J Physiol 274:R1212-R1219, 1998
24. 3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol 266:R1371-R1382, 1994
25. 3-adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Diabetes 45:909-914, 1996
26. 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes 20:428-434, 1996
27. 3-adrenergic receptor (Abstract). Obes Res 5 (Suppl. 1):O18, 1997
28. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 17), p. 45-51
29. Mazess RB, Barden HS, Bisek, JP Hanson J: Dual-energy X-ray absorptiometry for total body and regional bone mineral and soft tissue composition. Am J Clin Nutr 55:950-954, 1990
30. Bogardus C, Lillioja S, Mott D, Reaven G, Kashiwagi A, Foley JE: Relationship between obesity and maximal stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest 78:1568-1578, 1984
31. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
32. Bogardus C, Lillioja S, Ravussin E: Familial dependence of the resting metabolic rate. N Engl J Med 315:96-100, 1986
33. Lusk G: Analysis of the oxidation of mixtures of carbohydrate and fat: a correction. J Biol Chem 59:41-12, 1924
34. Lillioja S, Bogardus C: Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 4:517-540, 1988
35. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C: Determinants of 24-hour energy expenditure in man: method and results using a respiratory chamber. J Clin Invest 78:1568-1578, 1986
36. Best JD, Judzewitsch RG, Pfeifer MA, Beard JC, Halter JB, Porte D Jr: The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes 31:333-338, 1982
37. Arch JRS: The brown adipocyte β-adrenoceptor. Proc Nutr Soc 48:215-223, 1989
38. 3-adrenergic receptor. Science 241:1118-1121, 1989
39. 3-adrenergic receptor mRNA in man. J Clin Invest 91:344-349, 1993
40. 3-adrenergic receptor in human white adipose tissue. J Mol Endocrinol 10:193-197, 1993
41. 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue. J Clin Endocrinol Metab 77:352-355, 1993
42. Van Liefde I, Van Ermen A, Vauquelin G: No functional atypical β-adrenergic receptor in human omental adipocytes. Life Sci 54:209-214, 1994
43. 3-adrenoceptor in man. Br J Pharmacol 44:264-270, 1993
44. 3-adrenoceptor in man. J Clin Invest 95:2239-2245, 1995
45. Mitchell TH, Ellis RDM, Smith SA, Robb G, Cawthorne MA: Effects of BRL 35315, a β-adrenergic agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. Int J Obes 13:757-766, 1989
46. Smith SA, Cawthorne MA, Fay LC, McCullough DA, Mitchell TH: Effect of a novel β-adrenoceptor agonist on insulin sensitivity in lean healthy male volunteers (Abstract). Diabetologia 37 (Suppl. 1):15A, 1994
47. 3-adrenergic receptor. Mol Pharmacol 40:895-899, 1991
48. 3-adrenergic agonists, and leptin. J Biol Chem 272:24129-24132, 1997
49. Ghorbani M, Himms-Hagen J: Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes 21:465-475, 1997
50. 3-adrenergic agonist induces a functional active uncoupling protein in fat and slow-twitch muscle fibers. Am J Physiol 274:E469-E475, 1998
51. 3-adrenoceptor selectivity of the dioxolan dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269:1000-1006, 1993
52. 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci U S A 89:4490-4494, 1992
53. Wilson S, Thurlby PL, Arch JRS: Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 65:113-119, 1987
54. 3-adrenoceptor agonist, reduces serum leptin in rats with diet- or aging-associated obesity, but not in Zucker rats with genetic (fa/fa) obesity. Int J Obes 22:63-65, 1998